Midazolam for CYP3A4 phenotyping

Phase 3Small molecule

Midazolam for CYP3A4 phenotyping is one of 19 small molecule programs targeting Alveolar Soft Part Sarcoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alveolar Soft Part SarcomaActive, not recruiting

Alveolar Soft Part SarcomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Alveolar Soft Part Sarcoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Phase 3

1 2

Crestor

AstraZeneca

Phase 3

1 3

Lanoxin

AAdvanz Pharma

Phase 3

1 4

Tecentriq

Roche

Phase 2

2 5

Keytruda

Merck & Co.

Phase 2

1 6

Votrient

Novartis

Phase 2

1 7

Sutent

Pfizer

Phase 2

1 8

Coumadin

AAbbott

Phase 2

1 9

Tylenol

KKenvue Brands

Phase 2

1 10

Inlyta

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Alveolar Soft Part Sarcoma

NCT03016819

Clinical

Trials by Indication[1]

Bariatric Surgery1 trial

Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

Unknown status·NNatalia Valadares de Moraes·Phase 4·NCT04049786·120 enrolled

Alveolar Soft Part Sarcoma1 trial

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Recruiting·AAdvenchen Laboratories, LLC·Phase 3·NCT03016819·325 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Midazolam for CYP3A4 phenotyping. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Midazolam for CYP3A4 phenotyping compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Midazolam for CYP3A4 phenotyping. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advenchen Laboratories, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAdvenchen Laboratories, LLC

Midazolam for CYP3A4 phenotyping

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Bariatric Surgery1 trial

Alveolar Soft Part Sarcoma1 trial

References

Drug Info

Quick Facts

Related News